Intra-Aortic Balloon Pump Counterpulsation during Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction and Cardiogenic Shock: Insights from the British Columbia Cardiac Registry

M. Bilal Iqbal1,2*, Simon D. Robinson1,2, Lillian Ding3, Anthony Fung4, Eve Aymong5, Albert W. Chan6, Steven Hodge7, Anthony Della Siega1,2, Imad J. Nadra1,2, British Columbia Cardiac Registry Investigators¶

1 Department of Cardiology, Victoria Heart Institute Foundation, Victoria, BC, Canada, 2 Department of Cardiology, Royal Jubilee Hospital, Victoria, BC, Canada, 3 Cardiac Services BC, Provincial Health Services Authority, Vancouver, BC, Canada, 4 Department of Cardiology, Vancouver General Hospital, Vancouver, BC, Canada, 5 Department of Cardiology, St. Paul's Hospital, Vancouver, BC, Canada, 6 Department of Cardiology, Royal Columbian Hospital, Vancouver, BC, Canada, 7 Department of Cardiology, Kelowna General Hospital, Kelowna, BC, Canada

¶ The individual members of the British Columbia Cardiac Registry Investigators are listed in the Acknowledgments.
* biqbal@excite.com

Abstract

Background
Cardiogenic shock complicating ST-elevation myocardial infarction (STEMI) is associated with significant morbidity and mortality. In the primary percutaneous coronary intervention (PPCI) era, randomized trials have not shown a survival benefit with intra-aortic balloon pump (IABP) therapy. This differs to observational data which show a detrimental effect, potentially reflecting bias and confounding. Without robust and valid risk adjustment, findings from non-randomized studies may remain biased.

Methods
We compared long-term mortality following IABP therapy in patients with cardiogenic shock undergoing PPCI during 2008–2013 from the British Columbia Cardiac Registry. We addressed measured and unmeasured confounding using propensity score and instrumental variable methods.

Results
A total of 12,105 patients with STEMI were treated with PPCI during the study period. Of these, 700 patients (5.8%) had cardiogenic shock. Of the patients with cardiogenic shock, 255 patients (36%) received IABP therapy. Multivariable analyses identified IABP therapy...
to be associated with increased mortality up to 3 years (HR = 1.67, 95% CI: 1.20–2.67, p<0.001). This association was lost in propensity-matched analyses (HR = 1.23, 95% CI: 0.84–1.80, p = 0.288). When addressing measured and unmeasured confounders, instrumental variable analyses demonstrated that IABP therapy was not associated with mortality at 3 years (Δ = 16.7%, 95% CI: -12.7%, 46.1%, p = 0.281). Subgroup analyses demonstrated IABP was associated with increased mortality in non-diabetics; patients not undergoing multivessel intervention; patients without renal disease and patients not having received prior thrombolysis.

Conclusions

In this observational analysis of patients with STEMI and cardiogenic shock, when adjusting for confounding, IABP therapy had a neutral effect with no association with long-term mortality. These findings differ to previously reported observational studies, but are in keeping with randomized trial data.

Introduction

Cardiogenic shock complicating acute ST-elevation myocardial infarction (STEMI) is associated with significant morbidity and mortality[1, 2]. Early revascularisation therapy has been shown to improve outcomes in these patients[1]. Despite the use of primary percutaneous coronary intervention (PPCI), mortality remains high[3]. The intra-aortic balloon pump (IABP) is the most widely used mechanical hemodynamic support device in acute cardiac care[4]. It improves diastolic blood pressure, thereby augmenting coronary perfusion and its afterload reduction properties reduce myocardial oxygen consumption and increase cardiac output[5]. These physiological principles would suggest that IABP therapy might improve outcomes for patients with cardiogenic shock. In the PPCI era, observational studies have shown that IABP therapy is associated with increased mortality[6], whilst randomized trial data have shown a neutral effect[7]. This discrepancy may reflect bias and confounding inherent to observational studies and even with traditional methods of adjustment, residual confounding is expected[8]. We conducted an observational analysis to explore the relationship between IABP therapy and long-term mortality in patients receiving PPCI for STEMI with cardiogenic shock and utilized statistical approaches to address measured and unmeasured confounding.

Methods

This was a retrospective observational cohort study to investigate the relationship between long-term survival and IABP use at the time of PPCI for patients presenting with STEMI and cardiogenic shock. We used merged datasets from the British Columbia Cardiac Registry.

British Columbia Cardiac Registry

The British Columbia Cardiac Registry (BCCR) collects demographic, clinical and procedural data on all patients who undergo invasive cardiac procedures in British Columbia. Data is collected prospectively from five tertiary cardiac centers and entered into a central database maintained by a dedicated management team. Mortality events are obtained by linkage of provincial Vital Statistics Database and are automatically entered into the BCCR which records the date of death for all patients.
Population study and design

We examined an observational cohort of consecutive patients treated with PPCI between 2008–2013 at all 5 cardiac centers in British Columbia, Canada. Patient and procedural details were recorded at the time of the procedure. Anonymous datasets with linked mortality data were used for analysis. Initially, we identified 12,105 patients with STEMI that were treated with PPCI. The BCCR only records cardiogenic shock status at the time of PCI procedure. Data on subsequent development of cardiogenic shock post-procedure during the hospital admission is not captured by the database. Of the patients with STEMI undergoing PPCI, 700 patients (5.8%) had cardiogenic shock at the time of the procedure and were therefore included in the final analysis.

Definitions and clinical outcomes

Cardiogenic shock was defined as a sustained (>30 minutes) episode of systolic blood pressure <90 mm Hg secondary to cardiac dysfunction, and/or the requirement for inotropic or mechanical support to maintain blood pressure and adequate systemic perfusion[9]. We analyzed all-cause mortality at 30 days, 1 year and 3 years.

Ethics

All patient identifiable information was removed prior to database merging and analysis. Ethical approval for this study was obtained from the University of British Columbia Ethics Board (H12-01628).

Statistical analyses

Patients were divided into "no IABP" and "IABP" groups. Non-categorical variables in our dataset had a skewed distribution, and thus were summarized using median (lower and upper quartiles) and compared using the Mann-Whitney U-test. Categorical variables were expressed as percentages and compared using the Z-test. All statistical analyses were performed using MedCalc v12.5 (MedCalc Software, Ostend, Belgium) and R (Foundation for Statistical Computing, Vienna, Austria). Statistical significance was established at p<0.05 (2-tailed) for all tests.

(a) Multivariable-adjusted models for mortality. To determine independent predictors for mortality, Cox proportional hazards regression models were used to provide adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). The proportional hazards assumption was tested and verified with Schoenfeld residuals. To guide selection of significant variables for the final multivariable model, we initially adjusted for age, sex, diabetes, GP2b-3a inhibitor use, previous MI, previous history of revascularization, hypertension, hypercholesterolemia, renal disease, previous cerebrovascular accident, peripheral vascular disease, smoking, history of heart failure, radial access, vessel intervened upon (LMS, LAD, LCx, RCA, graft), pre-procedural thrombolysis, DES use, aspiration thrombectomy, severe LV dysfunction, multivessel disease, multivessel intervention, pulmonary disease, liver/gastrointestinal disease and malignancy using a stepwise variable selection process. The significant covariates from this were then included in the final multivariate model with IABP as a forced-in variable. Thus the covariates used in the final multivariate model were age, female sex, diabetes, renal disease, pre-procedural thrombolysis, LMS intervention, proximal LAD intervention, multivessel intervention, GP2b-3a inhibitor use and IABP use. In this way, the number of variables was limited to 1 per ≥ 10 events to prevent over-fitting of the model. Cumulative mortality rates were also presented as Kaplan-Meier curves and compared with the log-rank test.

(b) Propensity Score Matching. To account for measured confounders, propensity matching was performed. To derive propensity scores (PS), a logistic regression model was
fitted for IABP therapy to patient demographics, clinical, anatomical and procedural variables. Propensity score matching was performed using nearest-neighbor matching and 1:1 matching without replacement using calipers set at 0.1[10]. Cumulative mortality rates were also presented as Kaplan-Meier curves and compared with a stratified log-rank test. The propensity score models were assessed using the receiver operator curve (ROC) analysis (c-statistic) and Hosmer-Lemeshow test. Covariate balance was assessed using absolute standardised differences in means for the propensity-matched cohorts, with differences less than 10% taken to indicate good balance[10]. Cox proportional hazards regression models and logistic regression models were then applied to the propensity-matched cohorts adjusting for the significant covariates identified from multivariate models and PSi (double-robust models)[11].

(c) Instrumental variable (IV) analysis. IV analysis is an econometric method used to remove the effects of hidden bias in observational studies[12]. An IV has 2 key characteristics: (a) it is highly correlated with the treatment and (b) does not independently affect the outcome, other than via its effects through the treatment, so that it is not associated with measured or unmeasured variables. The geographical treatment rate can serve as effective IV[8] and we demonstrated this to be the case with centre-specific IABP rate of use (low vs. high). The rate of IABP use was determined for each centre, and each center was classified as either as having "high" or "low" center -specific IABP rate of use depending on whether it was greater or smaller than the median rate of use. We initially performed unadjusted and adjusted linear regression, adjusting for the same covariates as in the Cox proportional hazards models (as above). An adjusted IV analysis was performed using a simultaneous 2-stage least-squares regression approach. Finally, we adapted the theoretical framework proposed by Brookhart and Schneeweiss[13] to examine the strength of the IV across various patient subgroups. Adopting this framework, IABP use was determined for low vs. high centre IABP rates for each covariate. If the variation in IABP use induced by the IV for each covariate is larger or smaller than that observed in the overall cohort, it is possible that variation across unmeasured factors may bias the estimates for the effect of IABP in the population under study.

**Results**

**Baseline population and procedural characteristics**

We analyzed 700 consecutive patients who underwent PPCI for STEMI with cardiogenic shock across all 5 tertiary cardiac centers in British Columbia. Of this patient population, 225 patients received IABP therapy (32%) and 475 patients did not receive IABP therapy (68%). The trends in IABP use over the study period are shown in Fig 1. Patients receiving IABP therapy were more likely to have renal disease; have previous revascularization; have severe LV dysfunction; have multivessel disease; receive GP 2b-3a inhibitor; undergo transfemoral intervention; receive LMS/LAD intervention; undergo multivessel intervention; and have poor pre- and post procedural TIMI flow. The patient characteristics are summarized in Table 1.

**Unadjusted mortality**

The use of IABP was associated with higher mortality at 30 days (38.2% vs. 17.9%, p<0.001); 1 year (44.9% vs. 22.7%, p<0.001); and 3 years (47.1% vs. 26.3%, p<0.001).

**Cox proportional hazards regression models for mortality**

When adjusting for baseline clinical, anatomical and procedural variables, multivariable-adjusted analyses identified IABP use as an independent predictor for mortality at 30 days.
(HR = 2.02, 95% CI:1.40–2.91, p<0.001); 1 year (HR = 1.87, 95% CI:1.34–2.61, p<0.001); and 3 years (HR = 1.67, 95% CI:1.20–2.67, p<0.001).

Propensity matched analyses

Propensity score (PSi) matching yielded a total of 278 matched patients (139 patients in each group). The c-statistics for the PSi model was 0.86 and Hosmer-Lemeshow test yielded a p = 0.651. Table 2 illustrates that the baseline demographics, clinical, anatomical and procedural variables were well balanced in the propensity-matched cohorts and the absolute standardized differences were all less than 10% (Fig 2). IABP use demonstrated a non-significant trend towards higher mortality at 30 days (34.5% vs. 26.6%, p = 0.152); but was not associated with higher mortality at 1 year (39.6% vs. 32.4%, p = 0.211); and 3 years (40.3% vs. 35.3%, p = 0.387). Multivariable-adjusted models demonstrated that IABP use was not associated with mortality at 30 days (HR = 1.37, 95% CI: 0.89–2.11, p = 0.146), 1 year (HR = 1.31, 95% CI: 0.89–1.94, p = 0.177); and 3 years (HR = 1.23, 95% CI: 0.84–1.80, p = 0.288). As a secondary analysis, when we performed propensity matching using a 1: many matching to utilize a greater patient pool (n = 348), IABP use was still not associated with mortality at 3 years (HR = 1.28, 95% CI: 0.89–1.82, p = 0.138).

Kaplan-Meier survival analyses

The Kaplan-Meier survival curves for the unmatched and propensity-matched cohorts are shown in Fig 2. When adjusting for measured confounding, there was no difference in long-term survival with IABP therapy (stratified log rank test p = 0.278).

Subgroup analyses

We performed subgroup analyses incorporating PSi as a covariate into the multivariable models[14]. This method allowed us to perform subgroup analyses where residual confounding was present despite standard adjustment methods. The results of the subgroup analyses are shown in Fig 3.

Instrumental variable analyses

To account for unmeasured confounding, IV analysis was performed using centre-specific IABP rate of use (low vs. high) as an IV. The use of IABP was 12.8% vs. 42.5% (low vs. high groups, p<0.001), and the strong association between IABP use and the IV was validated using logistic and linear regression models. Multivariable models demonstrated that the IV was not associated with mortality and the F-test statistic for the IV was 70.81 (value <10 indicates a
Table 1. Baseline demographic and procedural characteristics for total study population.

| Clinical factors                  | Total (n = 700) | No IABP (n = 475) | IABP (n = 255) | p value |
|----------------------------------|----------------|-----------------|----------------|---------|
| **Age (years)**                  | 66(56,75)      | 65(56,75)       | 66(56,75)      | 0.732   |
| Female                           | 25.7           | 26.7            | 23.6           | 0.368   |
| PVD                              | 6.7            | 7.2             | 5.6            | 0.454   |
| Renal disease *                  | 12.1           | 9.3             | 18.0           | 0.002   |
| Previous CVA                     | 7.5            | 7.0             | 8.5            | 0.487   |
| Previous MI                      | 17.0           | 15.6            | 20.0           | 0.146   |
| Previous revascularization       | 19.3           | 16.8            | 25.4           | 0.012   |
| History of heart failure         | 16.0           | 14.6            | 19.0           | 0.148   |
| Diabetes                         | 24.2           | 23.1            | 26.6           | 0.315   |
| Hypertension                     | 48.9           | 49.0            | 48.8           | 0.969   |
| Hypercholesterolemia             | 34.9           | 36.0            | 32.5           | 0.386   |
| Smoking †                        | 28.3           | 32.0            | 20.6           | 0.003   |
| Severe LV (EF <30%)              | 23.1           | 12.7            | 47.6           | <0.001  |
| Pulmonary disease                | 12.0           | 12.2            | 11.5           | 0.811   |
| Gastrointestinal disease         | 10.2           | 10.4            | 9.7            | 0.776   |
| Malignancy                       | 6.5            | 6.8             | 5.8            | 0.643   |
| **Coronary anatomy ‡**           |                |                 |                |         |
| LMS                              | 9.0            | 5.9             | 15.7           | <0.001  |
| LAD                              | 77.4           | 72.6            | 87.4           | <0.001  |
| proximal LAD                     | 39.4           | 34.1            | 50.7           | <0.001  |
| non-proximal LAD                 | 62.9           | 56.6            | 76.2           | <0.001  |
| LCx                              | 57.9           | 52.4            | 69.5           | <0.001  |
| RCA                              | 69.3           | 67.6            | 73.1           | 0.141   |
| Multivessel disease              | 70.8           | 65.3            | 82.5           | <0.001  |
| **Procedural characteristics**   |                |                 |                |         |
| Pre-procedural thrombolysis      | 14.6           | 17.5            | 8.4            | 0.002   |
| Radial access                    | 23.9           | 33.7            | 3.1            | <0.001  |
| GP 2b/3a inhibitor use           | 25.0           | 21.9            | 31.6           | 0.005   |
| Thrombectomy                     | 30.1           | 32.2            | 25.8           | 0.083   |
| DES use                          | 45.0           | 46.0            | 43.1           | 0.505   |
| Pre-procedural TIMI flow         |                |                 |                |         |
| TIMI 0–1                         | 95.1           | 93.0            | 99.5           | <0.001  |
| TIMI 2–3                         | 4.9            | 7.0             | 0.5            | <0.001  |
| Post-procedural TIMI flow        |                |                 |                |         |
| TIMI 0–1                         | 90.1           | 85.7            | 99.5           | <0.001  |
| TIMI 2–3                         | 9.9            | 14.3            | 0.5            | <0.001  |
| **Target vessel**                |                |                 |                |         |
| LMS                              | 6.6            | 3.4             | 13.5           | <0.001  |
| LAD                              | 48.1           | 42.7            | 59.6           | <0.001  |
| proximal LAD                     | 29.7           | 23.4            | 43.0           | <0.001  |
| non-proximal LAD                 | 33.4           | 30.1            | 40.4           | <0.001  |
| LCx                              | 27.1           | 21.5            | 39.0           | <0.001  |
| RCA                              | 43.7           | 46.9            | 36.8           | 0.011   |
| Graft                            | 1.1            | 1.3             | 0.9            | 0.672   |

(Continued)
Table 3 demonstrates the strength of centre-specific IABP rate as an IV. When comparing baseline variables, although there were differences in covariates between the groups, these differences were smaller and the overall covariate balance was better than that observed when stratifying patients according to IABP use (Table 1). However, such differences in covariates between IV-stratified groups are often reported in IV analyses[8, 15]. We also calculated the covariate imbalance using the Mahalanobis distance, which corrects for observed covariance among measured covariates. Stratification by the IV resulted in a 51% reduction in Mahalanobis distance, indicating a significant improvement in covariate balance. Adopting the framework proposed by Brookhart and Schneeweiss[13], when examining the difference in IABP use amongst various patient subsets stratified according to the IV, the strength of the IV was similar to that in the overall cohort across most observed variables, with the exception of 3 variables. The balance in the distribution of most observed variables provided reasonable evidence to infer that balance of unmeasured variables is likely to be improved by IV stratification. IABP was found to be associated with increased 3-year mortality, with an unadjusted mortality difference of 15.7% (95% CI: 8.4%, 30.0%, p < 0.001) and absolute mortality difference of 11.5% (95% CI: 3.7%, 19.3%, p = 0.004). However, when performing an IV analysis, this association was lost and the IV-adjusted mortality difference was 16.7% (95% CI: -12.7%, 46.1%, p = 0.281).

Discussion

In patients presenting with STEMI and cardiogenic shock, the benefit of IABP therapy continues to be debated. Randomized studies have not shown a survival benefit with IABP therapy, whilst non-randomized studies have largely shown increased mortality. Non-randomized studies may be hampered with bias and confounding and despite traditional adjustment methods, there is always residual confounding, largely attributable to unmeasured confounders. Our study represents the first observational study in this field to systematically address the issue of measured and unmeasured confounding. The results of this study have shown that using traditional adjustment methods, IABP therapy is an independent predictor of increased mortality up to 3 years, largely in keeping with previous reported observational analyses[16–20]. However, when adjusting for measured and unmeasured confounders, this association was lost, and the results were in keeping with randomized trial data.

Pooled analyses of the studies with patients undergoing primary PCI demonstrate that IABP therapy is associated with increased mortality (30-day mortality difference = 6%, 95% CI, 3–10%, p<0.001)[6]. To date, there are 4 observational studies that have examined the benefit of IABP therapy in patients with cardiogenic shock in the primary PCI era[16–20]. The NRMI-
Table 2. Distribution of covariates in the propensity-matched cohorts.

| Clinical factors                  | Total (n = 278) | No IABP (n = 139) | IABP (n = 139) | p value | Sdiff |
|----------------------------------|----------------|------------------|----------------|---------|-------|
| **Age > 80 years**               | 18.7           | 19.4             | 18.0           | 0.758   | 3.7   |
| **Female**                       | 27.7           | 28.1             | 27.3           | 0.893   | 1.6   |
| **PVD**                          | 5.0            | 4.6              | 5.5            | 0.754   | 3.9   |
| **Renal disease**                | 15.5           | 15.7             | 15.4           | 0.946   | 0.9   |
| **Previous CVA**                 | 10.1           | 10.8             | 9.4            | 0.710   | 4.6   |
| **Previous MI**                  | 19.1           | 19.4             | 18.7           | 0.879   | 1.8   |
| **Previous revascularization**   | 21.6           | 21.6             | 21.6           | 1.000   | 0.0   |
| **History of heart failure**     | 18.1           | 18.6             | 17.6           | 0.835   | 2.6   |
| **Diabetes**                     | 26.5           | 25.2             | 27.9           | 0.677   | 6.2   |
| **Hypertension**                 | 47.7           | 45.7             | 49.6           | 0.535   | 7.8   |
| **Hypercholesterolemia**         | 31.1           | 31.3             | 31.0           | 0.959   | 0.6   |
| **Smoking †**                    | 24.3           | 25.6             | 23.0           | 0.633   | 6.0   |
| **Severe LV (EF<30%)**           | 27.6           | 27.8             | 27.4           | 0.950   | 0.9   |
| **Pulmonary disease**            | 14.6           | 15.6             | 13.5           | 0.630   | 6.1   |
| **Gastrointestinal disease**     | 9.5            | 9.4              | 9.6            | 0.967   | 0.5   |
| **Malignancy**                   | 6.7            | 7.0              | 6.4            | 0.854   | 2.3   |
| **Coronary anatomy ‡**           |                |                  |                |         |       |
| **LMS**                          | 10.4           | 10.1             | 10.8           | 0.844   | 2.4   |
| **LAD**                          | 80.6           | 79.1             | 82.0           | 0.544   | 7.3   |
| **proximal LAD**                 | 41.4           | 39.6             | 43.2           | 0.543   | 7.3   |
| **non-proximal LAD**             | 70.1           | 69.1             | 71.2           | 0.694   | 4.7   |
| **LCx**                          | 60.8           | 59.0             | 62.6           | 0.539   | 7.4   |
| **RCA**                          | 70.5           | 70.5             | 70.5           | 1.000   | 0.0   |
| **Multivessel disease**          | 75.2           | 75.5             | 74.8           | 0.890   | 1.7   |
| **Procedural characteristics**   |                |                  |                |         |       |
| **Pre-procedural thrombolysis**  | 10.1           | 10.1             | 10.1           | 1.000   | 0.0   |
| **Radial access**                | 5.4            | 5.8              | 5.0            | 0.791   | 3.2   |
| **GP 2b/3a inhibitor use**       | 27.7           | 27.3             | 28.1           | 0.893   | 1.6   |
| **Thrombectomy**                 | 28.8           | 27.3             | 30.2           | 0.596   | 6.4   |
| **DES use**                      | 44.4           | 44.3             | 44.4           | 0.806   | 0.4   |
| **Post-procedural TIMI flow**    |                |                  |                |         |       |
| **TIMI 0–1**                     | 99.2           | 99.2             | 99.2           | 0.982   | 0.3   |
| **TIMI 2–3**                     | 0.8            | 0.8              | 0.8            | 0.982   | 0.3   |
| **Target vessel**                |                |                  |                |         |       |
| **LMS**                          | 6.8            | 7.2              | 6.5            | 0.812   | 2.9   |
| **LAD**                          | 47.1           | 46.0             | 48.2           | 0.719   | 4.3   |
| **proximal LAD**                 | 30.6           | 30.2             | 30.9           | 0.896   | 1.6   |
| **non-proximal LAD**             | 34.5           | 35.3             | 33.8           | 0.801   | 3.0   |
| **LCx**                          | 31.7           | 33.1             | 30.2           | 0.606   | 6.2   |
| **RCA**                          | 41.4           | 41.7             | 41.0           | 0.903   | 1.5   |
| **Graft**                        | 1.4            | 1.4              | 1.4            | 1.000   | 0.0   |
| **Multivessel intervention**     | 26.7           | 28.1             | 25.4           | 0.587   | 6.1   |

Discrete variables are presented as percentages and compared using the Z-test (2-tailed); Continuous data presented as medians (25% IQ, 75% IQ) and compared using the Mann-Whitney U-test (2-tailed). All variables were also compared using absolute standardized difference in means (%) (Sdiff).

* Renal disease was defined as serum creatinine >150mmol/l or renal replacement therapy.
† Smoking was defined as smoking of ≥1 cigarettes/day and had smoked in the month preceding PCI
‡ A diseased epicardial coronary vessel was defined as having a >50% coronary stenosis by visual estimation.

Abbreviations are as for Table 1.
The IABP therapy for STEMI and Cardiogenic Shock study represents the earliest and largest of these (n = 8671) and found IABP therapy to be associated with increased in-hospital mortality, despite multivariable adjustment and using propensity score methods (OR = 1.27, 95% CI: 1.07–1.50)\(^\text{[18]}\). The observed detrimental effect of IABP therapy as an adjunct to primary PCI in STEMI with cardiogenic shock is contrary to the expectation that IABP might improve survival in these patients and the reasons for this remain speculative. A systemic inflammatory response to the device, as well the increase in access-site complications may be contributory\(^\text{[19]}\). However, the results of these observational analyses need to be interpreted with caution, as one cannot exclude the presence of confounders. Although the NRMI-2 study\(^\text{[18]}\) adjusted for measured confounders it did not specifically address unmeasured confounders. Importantly, IABP therapy may have been given to the sicker patients, which would induce a severe bias towards poor outcomes in the IABP group.

The IABP-SHOCK II trial was a randomized evaluation of IABP therapy for acute myocardial infarction and cardiogenic shock in 600 patients, and represents the largest randomized body of evidence in this field\(^\text{[7]}\). IABP therapy had a neutral effect with no difference in 30-day mortality (RR = 0.96; 95% CI: 0.79–1.17, p = 0.69)\(^\text{[7]}\). Importantly, there was no divergence in the mortality curves, as was seen with the long-term results of the earlier IABP trials\(^\text{[21]}\), and the results were sustained up to 1 year (RR = 1.01; 95% CI: 0.86–1.18, p = 0.91)\(^\text{[22]}\). These data have challenged the notion that IABP therapy would improve outcomes by augmenting coronary perfusion. The lack of benefit may reflect the fact that the hemodynamic improvement
with IABP and its effect on cardiac output is only modest with an absolute increase in cardiac output of 0.5 L/min [5], which might not be sufficient to reduce mortality. The insertion of IABP before coronary revascularization may improve procedural safety by improving left ventricular unloading [23], but data regarding this is somewhat conflicting [23, 24]. In the IABP SHOCK II trial, there was no mortality benefit in patients in whom the IABP was inserted before revascularization, as compared to after revascularization [7].

Similar to previous observational studies [16–20], the IABP population in our study was representative of the sicker and higher risk patient population. Using standard adjustment methods, we found IABP therapy was associated with increased mortality [16–18]. However, when adjusting for measured confounding using propensity-matched analyses, this association was lost. This loss of association with IABP therapy and mortality following propensity-matching has been reported in patients with STEMI [25]. However, a limitation with propensity-matched analyses, particularly when the treated group is small and with standard 1:1 matching, is that the overall study population analyzed is reduced, e.g. our propensity matched cohort of 278 patients represented 40% of the total study cohort. We addressed this with a 1:many matching algorithm, but despite this, IABP was still not associated with mortality. These results differ to those from the NRMI 2 study which demonstrated worse outcomes with IABP therapy despite adjustment using propensity score methods [18]. Whilst these differences may reflect unmeasured confounders, they may also be explained by the differences in the study cohorts. Compared to our study, the NRMI2 study cohort was a higher risk cohort exhibiting greater mortality rates. In the NRMI-2 study, patients were older; and comprised of both non-STEMI (63%) and STEMI (37%) patients compared to our study that exclusively had STEMI patients. The mortality of patients with non-STEMI and cardiogenic shock is significantly greater than those with STEMI and cardiogenic shock [26]. We also addressed unmeasured confounding using IV analyses, a recognized method for addressing treatment selection by unmeasured factors. These analyses confirmed findings from the propensity-matched cohorts. This study demonstrates how systematically addressing bias using propensity score and instrumental variable methods can reduce the gap between randomized trials and real world observational analyses.

![Fig 3. Subgroup analyses in select patient groups. Multivariable adjusted models for 3 year mortality referent to IABP therapy. There were no significant interactions by subgroups.](doi:10.1371/journal.pone.0148931.g003)
Table 3. Examining the strength of centre-specific rate of IABP use as an instrumental variable.

| Clinical factors       | Centre IABP use | IABP use within each subgroup according to instrumental variable | % difference in IABP use | IABP Therapy for STEMI and Cardiogenic Shock |
|------------------------|-----------------|-----------------------------------------------------------------|--------------------------|---------------------------------------------|
|                        | Centre IABP use | % difference in IABP use (95% CI)                               | Low (n = 243)            | High (n = 457)                              |
|                        | Low (n = 243)   | High (n = 457)                                                 |                          |                                             |
| Age > 80 years         | 13.6            | 16.6                                                          | 12.5                    | 33.2                                       |
| Female                 | 26.3            | 25.4                                                          | 14.3                    | 29.1                                       |
| PVD                    | 9.1             | 5.5                                                           | -2.2                    | 29.5                                       |
| Renal disease          | 7.2             | 14.7                                                          | 20.2                    | 47.3                                       |
| Previous CVA           | 6.4             | 8.0                                                           | 0.4                     | 32.3                                       |
| Previous MI            | 17.7            | 16.6                                                          | 16.9                    | 35.8                                       |
| Previous revascularization | 13.6         | 20.8                                                          | 21.9                    | 40.5                                       |
| History of heart failure | 18.0          | 15.1                                                          | 9.8                     | 31.6                                       |
| Diabetes               | 22.2            | 26.0                                                          | 15.8                    | 32.5                                       |
| Hypertension           | 51.6            | 48.4                                                          | 18.5                    | 29.7                                       |
| Hypercholesterolemia   | 35.4            | 36.7                                                          | 15.6                    | 28.8                                       |
| Smoking                | 38.4            | 21.7                                                          | 9.7                     | 23.5                                       |
| Severe LV (EF <30%)    | 10.1            | 28.9                                                          | 37.6                    | 59.2                                       |
| Pulmonary disease      | 12.0            | 12.0                                                          | 11.4                    | 34.7                                       |
| Gastrointestinal disease | 9.2             | 10.6                                                          | 18.3                    | 42.9                                       |
| Malignancy             | 6.9             | 6.2                                                           | 7.8                     | 39.8                                       |
| Coronary anatomy       |                 |                                                               |                         |                                             |
| LMS                    | 8.6             | 9.2                                                           | 27.1                    | 56.6                                       |
| LAD                    | 76.1            | 78.0                                                          | 20.2                    | 29.2                                       |
| proximal LAD           | 38.7            | 39.8                                                          | 19.8                    | 33                                           |
| non-proximal LAD       | 56.0            | 66.6                                                          | 22.7                    | 32.8                                       |
| LCx                    | 51.0            | 61.5                                                          | 23.1                    | 33.6                                       |
| RCA                    | 67.5            | 70.3                                                          | 18.7                    | 27.9                                       |
| Multivessel disease    | 67.1            | 72.7                                                          | 21.6                    | 39.9                                       |
| Procedural characteristics |                 |                                                               |                         |                                             |
| Pre-procedural thrombolysis | 28.0       | 7.4                                                           | -7.8                    | 9.8                                         |
| Radial access          | 41.6            | 14.4                                                          | -3.2                    | 4.5                                         |
| GP 2b/3a inhibitor use | 3.8             | 45.4                                                          | 30.5                    | 46                                           |
| Thrombectomy           | 35.4            | 27.4                                                          | 9.4                     | 22.9                                       |
| DES use                | 41.8            | 46.7                                                          | 21                      | 32.5                                       |
| Target vessel          |                 |                                                               |                         |                                             |
| LMS                    | 4.9             | 7.5                                                           | 28.2                    | 63.6                                       |
| LAD                    | 47.3            | 48.6                                                          | 22.3                    | 40                                           |
| proximal LAD           | 26.7            | 31.2                                                          | 24.8                    | 40.4                                       |
| non-proximal LAD       | 28.4            | 36.0                                                          | 26.7                    | 40.2                                       |
| LCx                    | 20.2            | 30.8                                                          | 27.2                    | 43.3                                       |
| RCA                    | 43.6            | 43.7                                                          | 14.3                    | 25.2                                       |
| Graft                  | 1.2             | 1.1                                                           | -17.9                   | 65.1                                       |
| Multivessel intervention | 16.7          | 26.0                                                          | 31.5                    | 49.6                                       |

IABP use as a % of the full cohort:
4.4                    27.7  23.3  (16.5–30)

Distribution of covariates between the groups and IABP use within each subgroup when stratified IV (expressed as %). * indicates where variation in IABP use induced by the instrument for each covariate was larger or smaller than that observed in the overall cohort.

doi:10.1371/journal.pone.0148931.t003
Whether or not IABP therapy may be beneficial in select patient sub-groups remains to be determined, and the results from subgroup analyses of the IABP-SHOCK II trial were inconclusive[7]. Given the residual confounding with standard adjustment methods, we performed subgroup analyses using propensity-score adjusted models. Specifically, this demonstrated that IABP therapy was associated with increased long-term mortality in non-diabetic patients and those not undergoing multivessel intervention. Diabetic patients have greater coronary disease burden are more likely to have diffuse distal disease[27, 28]. Thus diabetic patients and particularly those undergoing multivessel intervention are more likely to have an increased ischemic burden, and the results from the subgroup analyses would suggest that these patients might benefit from IABP therapy. We observed a strong trend for worse outcomes in patients without renal disease. This is contrary to common perception that IABP therapy may compromise renal blood flow, and potentially compromise renal function in those with pre-existing renal disease, which may contribute to adverse outcomes. However, a possible explanation for our finding is that patients with renal disease are more likely to represent those with severe coronary disease and greater ischemic burden, who are more likely to derive benefit from IABP therapy. We also observed worse outcomes in those not receiving pre-procedural thrombolysis, suggesting possible benefit of IABP therapy in those undergoing rescue PCI following thrombolysis. This would be in keeping with findings from earlier studies in the thrombolysis era suggesting a benefit of IABP therapy following thrombolysis[6]. It is important to note that given the reduction in sample size in sub-group analyses, the power to detect differences is reduced. As such, the results of the sub-group analyses should be interpreted with caution. Whilst the presented subgroup analyses provide an interesting perspective, the findings should only be considered hypothesis generating. They must not distract us from the main finding of the study, where IABP had a neutral effect with respect to long-term mortality in patients undergoing PPCI for STEMI.

The main strength of this study is that it is the largest reported analysis examining IABP therapy exclusively in patients with STEMI and cardiogenic shock with the longest reported follow-up and addresses measured and unmeasured confounding. This study has all the limitations of a registry and all the potential bias associated with non-randomization, and despite our rigorous attempts to address confounding, residual confounding cannot be excluded. Data with regards to ventilation status, ischemic times, inotropic support, timing of IABP insertion (pre- or post revascularization) and peri-procedural hemodynamic data were not available. It has been shown that in the contemporary era, despite a reduction in ischemic times, including patients with cardiogenic shock, the mortality rates have remained the same. Thus the lack of ischemic times in this study is a less significant limitation. However, the use of an IV approach should address the presence of unmeasured variables. Nevertheless, the results of our study indicate that when adjusting for confounding, IABP therapy for patients with STEMI and cardiogenic shock undergoing PPCI is not associated with survival, which is in keeping with randomized trial data.

Conclusions
In this observational analysis of patients with STEMI and cardiogenic shock undergoing PPCI, when adjusting for measured and unmeasured confounding, IABP therapy had a neutral effect and was not associated with long-term mortality. These findings differ to previously reported observational studies, but are in keeping with randomized trial data.

Acknowledgments
The British Columbia Cardiac Registry Investigators include: M. Bilal Iqbal, Simon D. Robinson, Lillian Ding, Anthony Fung, Eve Aymong, Albert W. Chan, Steven Hodge, Anthony Della Siega and Imad J. Nadra.
Author Contributions
Conceived and designed the experiments: MBI IJN. Performed the experiments: MBI SDR AF EA AWC SH ADS IJN. Analyzed the data: MBI LD SDR ADS IJN. Contributed reagents/materials/analysis tools: MBI SDR IJN. Wrote the paper: MBI SDR LD AF EA AWC SH ADS IJN.

References
1. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. The New England journal of medicine. 1999; 341:625–34. PMID:10460813
2. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. The New England journal of medicine. 1999; 340:1162–8. PMID:10202167
3. Zeymer U, Vogt A, Zahn R, Weber MA, Tebbe U, Gotthik M, et al. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). European heart journal. 2004; 25:322–8. PMID:14984921
4. Kantrowitz A, Tjonneland S, Freed PS, Phillips SJ, Butner AN, Sherman JL Jr. Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA: the journal of the American Medical Association. 1968; 203:113–8. PMID:5694059
5. Scheidt S, Wilner G, Mueller H, Summers D, Lesch M, Wolff G, et al. Intra-aortic balloon counterpulsation in cardiogenic shock. Report of a co-operative clinical journal of medicine. 1973; 288:979–84. PMID:4696253
6. Sjauw KD, Engstrom AE, Vis MM, van der Schaaf RJ, Baan J Jr., Koch KT, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? European heart journal. 2009; 30:459–68. doi:10.1093/eurheartj/ehn602 PMID:19168529
7. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. The New England journal of medicine. 2012; 367:1287–96. doi:10.1056/NEJMoa1208410 PMID: 22920912
8. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA: the journal of the American Medical Association. 2007; 297:278–85. PMID:17227979
9. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). Journal of the American College of Cardiology. 2001; 38:2114–30. PMID:11738323
10. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Statistics in medicine. 2007; 26:734–53. PMID:16708349
11. Valgimigli M, Saia F, Guastaroba P, Menozzi A, Magnacavici P, Santarelli A, et al. Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (Registro regionale Angioplastiche dell’Emilia-Romagna) multicenter registry. JACC Cardiovascular interventions. 2012; 5:23–35.
12. McCiellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA: the journal of the American Medical Association. 1994; 272:859–66. PMID:8078163
13. Brookhart MA, Schneeweiss S. Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. The international journal of biostatistics. 2007; 3:Article 14.
14. Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiology and drug safety. 2012; 21:697–709. doi:10.1002/pds.2256 PMID:22162077
15. Venkitachalam L, Lei Y, Magnuson EA, Chan PS, Stolker JM, Kennedy KF, et al. Survival benefit with drug-eluting stents in observational studies: fact or artifact? Circulation Cardiovascular quality and outcomes. 2011; 4:587–94. doi:10.1161/CIRCOUTCOMES.111.960971 PMID:21988921
16. Vis MM, Sjauw KD, van der Schaaf RJ, Baan J Jr., Koch KT, DeVries JH, et al. In patients with ST-segment elevation myocardial infarction with cardiogenic shock treated with percutaneous coronary intervention, admission glucose level is a strong independent predictor for 1-year mortality in patients without a prior diagnosis of diabetes. American heart journal. 2007; 154:1184–90. PMID: 18035093

17. Vis MM, Sjauw KD, van der Schaaf RJ, Koch KT, Baan J Jr., Tijssen JG, et al. Prognostic value of admission hemoglobin levels in ST-segment elevation myocardial infarction patients presenting with cardiogenic shock. The American journal of cardiology. 2007; 99:1201–2. PMID: 17478141

18. Barron HV, Every NR, Parsons LS, Angeja B, Goldberg RJ, Gore JM, et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. American heart journal. 2001; 141:933–9. PMID: 11376306

19. Zeymer U, Hochadel M, Hauptmann KE, Wiegand K, Schuhmacher B, Brachmann J, et al. Intra-aortic balloon pump in patients with acute myocardial infarction complicated by cardiogenic shock: results of the ALKK-PCI registry. Clinical research in cardiology: official journal of the German Cardiac Society. 2013; 102:223–7.

20. Zeymer U, Bauer T, Hamm C, Zahn R, Weidinger F, Seabra-Gomes R, et al. Use and impact of intra-aortic balloon pump on mortality in patients with acute myocardial infarction complicated by cardiogenic shock: results of the Euro Heart Survey on PCI. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2011; 7:437–41.

21. Perera D, Stables R, Clayton T, de Silva K, Lumley M, Clack L, et al. Long-term mortality data from the balloon pump-assisted coronary intervention study (BCIS-1): a randomized, controlled trial of elective balloon counterpulsation during high-risk percutaneous coronary intervention. Circulation. 2013; 127:207–12. doi: 10.1161/CIRCULATIONAHA.112.132209 PMID: 23224207

22. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II); final 12 month results of a randomised, open-label trial. Lancet. 2013; 382:1638–45. doi: 10.1016/S0140-6736(13)61783-3 PMID: 24011548

23. Abdel-Wahab M, Saad M, Kynast J, Geist V, Sherif MA, Richardt G, et al. Comparison of hospital mortality with intra-aortic balloon counterpulsation insertion before versus after primary percutaneous coronary intervention for cardiogenic shock complicating acute myocardial infarction. The American journal of cardiology. 2010; 105:967–71. doi: 10.1016/j.amjcard.2009.11.021 PMID: 20346314

24. Cheng JM, van Leeuwen MA, de Boer SP, Wai MC, den Ulil CA, Jewbali LS, et al. Impact of intra-aortic balloon pump support initiated before versus after primary percutaneous coronary intervention in patients with cardiogenic shock from acute myocardial infarction. International journal of cardiology. 2013; 168:3758–63. doi: 10.1016/j.ijcard.2013.06.009 PMID: 23830073

25. Sjauw KD, Engstrom AE, Vis MM, Boom W, Baan J Jr., de Winter RJ, et al. Efficacy and timing of intra-aortic counterpulsation in patients with ST-elevation myocardial infarction complicated by cardiogenic shock. Netherlands heart journal: monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation. 2012; 20:402–9.

26. Anderson ML, Peterson ED, Peng SA, Wang TY, Ohman EM, Bhatt DL, et al. Differences in the profile, treatment, and prognosis of patients with cardiogenic shock by myocardial infarction classification: A report from NCDR. Circulation Cardiovascular quality and outcomes. 2013; 6:708–15. doi: 10.1161/CIRCOUTCOMES.113.000262 PMID: 24221834

27. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1996; 94:1818–25. PMID: 8873655

28. Dortimer AC, Shenoy PN, Shiroff RA, Leaman DM, Babb JD, Liedtke AJ, et al. Diffuse coronary artery disease in diabetic patients: fact or fiction? Circulation. 1978; 57:133–6. PMID: 618380